Center-Authored Papers

Filters: Author is Antin, Joseph H  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
W
Weisdorf DJ, Nelson G, Lee SJ, Haagenson M, Spellman S, Antin JH, Bolwell B, Cahn J-Y, Cervantes F, Copelan E et al..  2009.  Sibling versus unrelated donor allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia: refined HLA matching reveals more graft-versus-host disease but not less relapse.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 15(11):1475-8. Abstract
V
Vander Lugt MT, Braun TM, Hanash S, Ritz J, Ho VT, Antin JH, Zhang Q, Wong C-H, Wang H, Chin A et al..  2013.  ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death.. The New England journal of medicine. 369(6):529-39. Abstract
T
Tolar J, Deeg HJ, Arai S, Horwitz M, Antin JH, McCarty JM, Adams RH, Ewell M, Leifer ES, Gersten ID et al..  2012.  Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 18(7):1007-11. Abstract
Teira P, Battiwalla M, Ramanathan M, Barrett JA, Woo Ahn K, Chen M, Green JS, Saad A, Antin JH, Savani BN et al..  2016.  Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis.. Blood. 127(20):2427-2438. Abstract
S
Storb R, Antin JH, Cutler C.  2010.  Should methotrexate plus calcineurin inhibitors be considered standard of care for prophylaxis of acute graft-versus-host disease? Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 16(1 Suppl):S18-27. Abstract
Saito AM, Cutler C, Zahrieh D, Soiffer RJ, Ho VT, Alyea EP, Koreth J, Antin JH, Lee SJ.  2008.  Costs of allogeneic hematopoietic cell transplantation with high-dose regimens.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 14(2):197-207. Abstract
R
Ringdén O, Pavletic SZ, Anasetti C, Barrett JA, Wang T, Wang D, Antin JH, Di Bartolomeo P, Bolwell BJ, Bredeson C et al..  2009.  The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation.. Blood. 113(13):3110-8. Abstract
Richardson PG, Soiffer RJ, Antin JH, Uno H, Jin Z, Kurtzberg J, Martin PL, Steinbach G, Murray KF, Vogelsang GB et al..  2010.  Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 16(7):1005-17. Abstract
Richardson PG, Riches ML, Kernan NA, Brochstein JA, Mineishi S, Termuhlen AM, Arai S, Grupp SA, Guinan EC, Martin PL et al..  2016.  Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure.. Blood. Abstract
P
Pulsipher MA, Young NS, Tolar J, Risitano AM, Deeg HJ, Anderlini P, Calado R, Kojima S, Eapen M, Harris R et al..  2011.  Optimization of therapy for severe aplastic anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on severe aplastic anemia convened by the Blood and Marrow Transplant Clinical Trials Network,. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 17(3):291-9. Abstract
Porter DL, Alyea EP, Antin JH, DeLima M, Estey EH, Falkenburg FJH, Hardy N, Kroeger N, Leis J, Levine J et al..  2010.  NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 16(11):1467-503. Abstract
O
Oliansky DM, Antin JH, Bennett JM, Deeg HJ, Engelhardt C, Heptinstall KV, DeLima M, Gore SD, Potts RG, Silverman LR et al..  2009.  The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 15(2):137-72. Abstract
M
McClune BL, Woo Ahn K, Wang H-L, Antin JH, Artz AS, Cahn J-Y, Deol A, Freytes CO, Hamadani M, Holmberg LA et al..  2014.  Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 20(7):960-8. Abstract
McCarroll SA, Bradner JE, Turpeinen H, Volin L, Martin PJ, Chilewski SD, Antin JH, Lee SJ, Ruutu T, Storer BE et al..  2009.  Donor-recipient mismatch for common gene deletion polymorphisms in graft-versus-host disease.. Nature genetics. 41(12):1341-4. Abstract
Martin PS, Li S, Nikiforow S, Alyea EP, Antin JH, Armand P, Cutler CS, Ho VT, Kekre N, Koreth J et al..  2016.  Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34+ cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation.. Haematologica. 101(4):499-505. Abstract
Macmillan ML, Robin M, Harris AC, Defor TE, Martin PJ, Alousi A, Ho VT, Bolaños-Meade J, Ferrara JLM, Jones R et al..  2015.  A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 21(4):761-7. Abstract
L
Lindsley CR, Saber W, Mar BG, Redd R, Wang T, Haagenson MD, Grauman PV, Hu Z-H, Spellman SR, Lee SJ et al..  2017.  Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation.. The New England journal of medicine. 376(6):536-547. Abstract
Lee SJ, Kukreja M, Wang T, Giralt SA, Szer J, Arora M, Woolfrey AE, Cervantes F, Champlin RE, Gale RP et al..  2008.  Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia.. Blood. 112(8):3500-7. Abstract
K
Krishnan A, Pasquini MC, Logan B, Stadtmauer EA, Vesole DH, Alyea E, Antin JH, Comenzo R, Goodman S, Hari P et al..  2011.  Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.. The lancet oncology. Abstract
Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, Wadleigh M, DeAngelo DJ, Stone RM, Sakamaki H et al..  2009.  Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials.. JAMA : the journal of the American Medical Association. 301(22):2349-61. Abstract
Kollman C, Spellman SR, Zhang M-J, Hassebroek A, Anasetti C, Antin JH, Champlin RE, Confer DL, Dipersio JF, Fernandez-Viña M et al..  2015.  The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy.. Blood. Abstract
Kim S-Y, Le Rademacher J, Antin JH, Anderlini P, Ayas M, Battiwalla M, Carreras J, Kurtzberg J, Nakamura R, Eapen M et al..  2014.  Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy: efficacy of hematopoietic stem cell transplantation.. Haematologica. 99(12):1868-75. Abstract
Kekre N, Zhang Y, Zhang M-J, Carreras J, Ahmed P, Anderlini P, Atta EH, Ayas M, Boelens JJ, Bonfim C et al..  2017.  Effect of antithymocyte globulin source on outcomes of bone marrow transplantation for severe aplastic anemia.. Haematologica. Abstract
J
Jagasia M, Arora M, Flowers MED, Chao NJ, McCarthy PL, Cutler CS, Urbano-Ispizua A, Pavletic SZ, Haagenson MD, Zhang M-J et al..  2012.  Risk factors for acute GVHD and survival after hematopoietic cell transplantation.. Blood. 119(1):296-307. Abstract
Jacobsohn DA, Arora M, Klein JP, Hassebroek A, Flowers MED, Cutler CS, Urbano-Ispizua A, Bolwell BJ, Antin JH, Boyiadzis M et al..  2011.  Risk factors associated with increased nonrelapse mortality and with poor overall survival in children with chronic graft-versus-host disease.. Blood. 118(16):4472-9. Abstract